In the discovery and investigation of novel biomarkers, tissue immunohistochemistry (IHC) studies are critical. The important question has been how to translate the technology into the clinical laboratory for patient testing once a biomarker target has been identified. Dr. Nan Zhang, VP of Global Central Lab Services at Frontage Laboratories Inc., will provide a valuable update on the application of Tissue IHC in new biomarker development, selection between different types of IHC, and validation of the methodology to be used for patient testing in clinical trials.
Register to gain access to gated resources.
Thank you for registering!
You now have the option of downloading the resource or viewing the web version below.
To ensure good data yield, there are challenges encountered during NGS operations, especially with poor quality RNA or DNA material, which is a common scenario for clinical samples. In this poster, we showcase three key tricks during the NGS operations to generate consistent data with high quality.
In this white paper, we detail IVRT methods pertaining to generic and innovator products and discuss their potential benefits in terms of quality, time, and cost. An associated case study illustrates key design and formulation considerations and ways to avoid common pitfalls.
In this Q&A, Nan Zhang MD PhD, Vice President of Global Central Lab and Biomarker Services at Frontage, speaks on the role of analytical and central laboratories in providing accurate laboratory data and seamless logistics services.